Critical Comparison: Silk Road Medical (SILK) versus Its Rivals

Silk Road Medical (NASDAQ: SILK) is one of 132 public companies in the “Surgical & medical instruments” industry, but how does it weigh in compared to its rivals? We will compare Silk Road Medical to related businesses based on the strength of its earnings, valuation, institutional ownership, dividends, profitability, risk and analyst recommendations.


This table compares Silk Road Medical and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Silk Road Medical -82.73% -165.90% -27.44%
Silk Road Medical Competitors -553.08% -106.56% -23.09%

Earnings and Valuation

This table compares Silk Road Medical and its rivals gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Silk Road Medical $63.35 million -$52.42 million -24.48
Silk Road Medical Competitors $1.42 billion $151.26 million -48.54

Silk Road Medical’s rivals have higher revenue and earnings than Silk Road Medical. Silk Road Medical is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a summary of current ratings and price targets for Silk Road Medical and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Silk Road Medical 0 1 4 0 2.80
Silk Road Medical Competitors 1152 3659 6039 350 2.50

Silk Road Medical presently has a consensus price target of $46.20, suggesting a potential upside of 38.79%. As a group, “Surgical & medical instruments” companies have a potential upside of 37.71%. Given Silk Road Medical’s stronger consensus rating and higher probable upside, equities analysts plainly believe Silk Road Medical is more favorable than its rivals.

Insider and Institutional Ownership

93.2% of Silk Road Medical shares are owned by institutional investors. Comparatively, 48.3% of shares of all “Surgical & medical instruments” companies are owned by institutional investors. 15.1% of shares of all “Surgical & medical instruments” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Silk Road Medical Company Profile

Silk Road Medical, Inc. operates as a medical device company in the United States. It offers ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and initiate temporary blood flow reversal; ENROUTE Transcarotid Stent System, a self-expanding, self-tapering stent with clinical data regarding lasting safety outcomes; ENHANCE Transcarotid Peripheral Access Kit for use in gaining initial access to the common carotid artery; and ENROUTE 0.014 Guidewire for navigating and crossing the target lesion for delivery of interventional devices. The company was founded in 2007 and is headquartered in Sunnyvale, California.

Receive News & Ratings for Silk Road Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silk Road Medical and related companies with's FREE daily email newsletter.